The hematopoietic cell transplantation-specific comorbidity index (HCT-CI) is an outcome predictor for partially matched related donor transplantation

American Journal of Hematology

Volumn 88, Issue 6, 2013, Pages 497-502

  Mo, Xiao Dong ^a   Xu, Lan Ping ^a   Liu, Dai Hong ^a   Zhang, Xiao Hui ^a   Chen, Huan ^a   Chen, Yu Hong ^a   Han, Wei ^a   Wang, Yu ^a   Wang, Feng Rong ^a   Wang, Jing Zhi ^a   Liu, Kai Yan ^a   Huang, Xiao Jun ^a  

^a PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTARABINE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; THYMOCYTE ANTIBODY;

ADOLESCENT; ADULT; ARTICLE; CAUSE OF DEATH; CHILD; CLINICAL ASSESSMENT TOOL; COMORBIDITY; DISEASE SEVERITY; DONOR; FEMALE; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC CELL TRANSPLANTATION SPECIFIC COMORBIDITY INDEX; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INCIDENCE; LIVER DISEASE; LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PARTIALLY MATCHED RELATED DONOR; PATIENT MONITOR; PREDICTIVE VALUE; PRESCHOOL CHILD; PRIORITY JOURNAL; RELAPSE; RISK FACTOR; SCHOOL CHILD; WHOLE BODY RADIATION;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; COMORBIDITY; FEMALE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; RECURRENCE; RESEARCH DESIGN; RISK FACTORS; SURVIVAL ANALYSIS; TISSUE DONORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84878171128     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23443     Document Type: Article

References (42)

1. Lu DP, Dong L, Wu T, et al. Conditioning including antithymocyte globulin followed by unmanipulated HLA-mismatched/haploidentical blood and marrow transplantation can achieve comparable outcomes with HLA-identical sibling transplantation. Blood 2006;107:3065-3073.
2. Huang XJ, Chang YJ. Unmanipulated HLA-mismatched/haploidentical blood and marrow hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2011;17:197-204.
3. Sorror ML. Comorbidities and hematopoietic cell transplantation outcomes. Hematology Am Soc Hematol Educ Program 2010;2010:237-247.
4. Sorror ML, Maris MB, Storb R, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: A new tool for risk assessment before allogeneic HCT. Blood 2005;106:2912-2919.
5. Smith AR, Majhail NS, MacMillan ML, et al. Hematopoietic cell transplantation comorbidity index predicts transplantation outcomes in pediatric patients. Blood 2011;117:2728-2734.
6. Sorror ML, Sandmaier BM, Storer BE, et al. Comorbidity and disease status based risk stratification of outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic cell transplantation. J Clin Oncol 2007;25:4246-4254.
7. Sorror ML, Giralt S, Sandmaier BM, et al. Hematopoietic cell transplantation specific comorbidity index as an outcome predictor for patients with acute myeloid leukemia in first remission: Combined FHCRC and MDACC experiences. Blood 2007;110:4606-4613.
8. Pollack SM, Steinberg SM, Odom J, et al. Assessment of the hematopoietic cell transplantation comorbidity index in non-Hodgkin lymphoma patients receiving reduced-intensity allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2009;15:223-230.
9. Sperr WR, Wimazal F, Kundi M, et al. Comorbidity as prognostic variable in MDS: Comparative evaluation of the HCT-CI and CCI in a core dataset of 419 patients of the Austrian MDS Study Group. Ann Oncol 2010;21:114-119.
10. Raimondi R, Tosetto A, Oneto R, et al. Validation of the Hematopoietic Cell Transplantation-Specific Comorbidity Index: A prospective, multicenter GITMO study. Blood 2012;120:1327-1333.
11. Sorror M, Storer B, Sandmaier BM, et al. Hematopoietic cell transplantation-comorbidity index and Karnofsky performance status are independent predictors of morbidity and mortality after allogeneic nonmyeloablative hematopoietic cell transplantation. Cancer 2008;112:1992-2001.
12. Lim ZY, Ingram W, Brand R, et al. Impact of pretransplant comorbidities on alemtuzumab-based reduced-intensity conditioning allogeneic hematopoietic SCT for patients with high-risk myelodysplastic syndrome and AML. Bone Marrow Transplant 2010;45:633-639.
13. Labonté L, Iqbal T, Zaidi MA, et al. Utility of comorbidity assessment in predicting transplantation-related toxicity following autologous hematopoietic stem cell transplantation for multiple myeloma. Biol Blood Marrow Transplant 2008;14:1039-1044.
14. Huang XJ, Liu DH, Liu KY, et al. Haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for the treatment of hematological malignancies. Bone Marrow Transplant 2006;38:291-297.
15. Przepiorka D, Weisdorf D, Martin P, et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995;15:825-828.
16. Filipovich AH, Weisdorf D, Pavletic S, et al. National institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease. I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005;11:945-956.
17. Kataoka K, Nannya Y, Ueda K, et al. Differential prognostic impact of pretransplant comorbidity on transplant outcomes by disease status and time from transplant: A single Japanese transplant centre study. Bone Marrow Transplant 2010;45:513-520.
18. Huang XJ, Wang Y, Liu DH, et al. Modified donor lymphocyte infusion (DLI) for the prophylaxis of leukemia relapse after hematopoietic stem cell transplantation in patients with advanced leukemia-feasibility and safety study. J Clin Immunol 2008;28:390-397.
19. Wang Y, Liu DH, Liu KY, et al. Long-term follow-up of haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for the treatment of leukemia: Nine years of experience at a single center. Cancer 2012;119:978-985.
20. Chen H, Liu KY, Xu LP, et al. Administration of imatinib after allogeneic hematopoietic stem cell transplantation may improve disease-free survival for patients with Philadelphia chromosome-positive acute lymphobla stic leukemia. J Hematol Oncol 2012;5:29.
21. Huang XJ, Liu DH, Liu KY, et al. Treatment of acute leukemia with unmanipulated HLA-mismatched/haploidentical blood and bone marrow transplantation. Biol Blood Marrow Transplant 2009;15:257-265.
22. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: New representations of old estimators. Stat Med 1999;18:695-706.
23. Scrucca L, Santucci A, Aversa F. Regression modeling of competing risk using R: An in depth guide for clinicians. Bone Marrow Transplant 2010;45:1388-1395.
24. Thomas X, Chelghoum Y. Cigarette smoking and acute leukemia. Leuk Lymphoma 2004;45:1103-1109.
25. Chiu BC, Gapstur SM, Greenland P, et al. Body mass index, abnormal glucose metabolism, and mortality from hematopoietic cancer. Cancer Epidemiol Biomarkers Prev 2006;15:2348-2354.
26. Extermann M. Interaction between comorbidity and cancer. Cancer Control 2007;14:13-22.
27. Bastard JP, Maachi M, Lagathu C, et al. Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur Cytokine Netw 2006;17:4-12.
28. Fernández-Real JM, Ricart W. Insulin resistance and chronic cardiovascular inflammatory syndrome. Endocr Rev 2003;24:278-301.
29. Sethi S, Mahler DA, Marcus P, et al. Inflammation in COPD: Implications for Management. Am J Med 2012;125:1162-1170.
30. Canhão H, Rodrigues AM, Mourão AF, et al. Comparative effectiveness and predictors of response to tumour necrosis factor inhibitor therapies in rheumatoid arthritis. Rheumatology (Oxford) 2012;51:2020-2026.
31. Huang YS, Hwang SJ, Chan CY, et al. Serum levels of cytokines in hepatitis C-related liver disease: A longitudinal study. Zhonghua Yi Xue Za Zhi (Taipei) 1999;62:327-333.
32. Szlosarek P, Charles KA, Balkwill FR. Tumour necrosis factor-alpha as a tumour promoter. Eur J Cancer 2006;42:745-750.
33. Cohen DH, Leroith D. Obesity, type 2 diabetes, and cancer: The insulin and IGF connection. Endocr Relat Cancer 2012;19:F27-F45.
34. Gallagher EJ, LeRoith D. Minireview: IGF, Insulin, and Cancer. Endocrinology 2011;152:2546-2551.
35. Abe S, Funato T, Takahashi S, et al. Increased expression of insulin-like growth factor i is associated with Ara-C resistance in leukemia. Tohoku J Exp Med 2006;209:217-228.
36. Aksoy S, Aksoy H, Harputluoglu H, et al. Treatment of comorbidities besides the treatment of primary tumor may further increase effective management of cancer. Med Hypotheses 2006;67:744-746.
37. Rosen LS. VEGF-targeted therapy: Therapeutic potential and recent advances. Oncologist 2005;10:382-391.
38. Simmons PJ, Przepiorka D, Thomas ED, Torok-Storb B. Host origin of marrow stromal cells following allogeneic bone marrow transplantation. Nature 1987;328:429-432.
39. Bernstein SH, Nademanee AP, Vose JM, et al. A multicenter study of platelet recovery and utilization in patients after myeloablative therapy and hematopoietic stem cell transplantation. Blood 1998;91:3509-3517.
40. Means RT Jr, Krantz SB. Progress in understanding the pathogenesis of the anemia of chronic disease. Blood 1992;80:1639-1647.
41. Xiao-Jun H, Lan-Ping X, Kai-Yan L, et al. Partially matched related donor transplantation can achieve outcomes comparable with unrelated donor transplantation for patients with hematologic malignancies. Clin Cancer Res 2009;15:4777-4783.
42. Chang YJ, Huang XJ. Haploidentical bone marrow transplantation without T-cell depletion. Semin Oncol 2012;39:653-663.